Erwan Bezard

List of Publications by Year
in descending order

246 papers	20,897 citations	7672 79 h-index	14012 133 g-index
256 all docs	256 docs citations	256 times ranked	22617 citing authors

#	Article	IF	Citations
1	Impaired brain insulin signalling in Parkinson's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	22
2	Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain, 2022, 145, 1001-1017.	3.7	14
3	In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity. Neurobiology of Disease, 2022, 162, 105579.	2.1	8
4	Similar neuronal imprint and no cross-seeded fibrils in Î±-synuclein aggregates from MSA and Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 10.	2.5	15
5	How Lazy Reading and Semantic Sloppiness May Harm Progress in Synucleinopathy Research. Biomolecules, 2022, 12, 228.	1.8	5
6	Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism. Brain, 2022, 145, 2092-2107.	3.7	18
7	Neurons with Catâ€™s Eyes: A Synthetic Strain of Î±-Synuclein Fibrils Seeding Neuronal Intranuclear Inclusions. Biomolecules, 2022, 12, 436.	1.8	8
8	Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?. Nature Reviews Neuroscience, 2022, 23, 115-128.	4.9	92
9	Acidic nanoparticles protect against Î±â€synucleinâ€induced neurodegeneration through the restoration of lysosomal function. Aging Cell, 2022, 21, e13584.	3.0	19
10	Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia. Npj Parkinson's Disease, 2022, 8, 41.	2.5	5
11	In vivo electrophysiological validation of DREADDâ€based modulation of pallidal neurons in the nonâ€human primate. European Journal of Neuroscience, 2021, 53, 2192-2204.	1.2	13
12	Lâ€DOPA regulates Î±â€synuclein accumulation in experimental parkinsonism. Neuropathology and Applied Neurobiology, 2021, 47, 532-543.	1.8	11
13	Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease, 2021, 148, 105184.	2.1	14
14	From <scp>iPS</scp> Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease. Movement Disorders, 2021, 36, 832-841.	2.2	10
15	Increased surface P2X4 receptor regulates anxiety and memory in P2X4 internalization-defective knock-in mice. Molecular Psychiatry, 2021, 26, 629-644.	4.1	32
16	Mass spectrometry imaging identifies abnormally elevated brain <scp>l</scp> -DOPA levels and extrastriatal monoaminergic dysregulation in <scp>l</scp> -DOPAâ€“induced dyskinesia. Science Advances, 2021, 7, .	4.7	29
17	Neuroprosthetic baroreflex controls haemodynamics after spinal cord injury. Nature, 2021, 590, 308-314.	13.7	96
18	Comparison of the expression and toxicity of AAV2/9 carrying the human A53T Î±-synuclein gene in presence or absence of WPRE. Heliyon, 2021, 7, e06302.	1.4	5

#	Article	IF	Citations
19	Evaluation of blood flow as a route for propagation in experimental synucleinopathy. Neurobiology of Disease, 2021, 150, 105255.	2.1	5
20	Adenosine A_{2A}R/A₁R Antagonists Enabling Additional H₃R Antagonism for the Treatment of Parkinsonâ€™s Disease. Journal of Medicinal Chemistry, 2021, 64, 8246-8262.	2.9	6
21	Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinsonâ€™s disease and L-Dopa induced dyskinesia. Communications Biology, 2021, 4, 1071.	2.0	12
22	Monitoring of a progressive functional dopaminergic deficit in the A53T-AAV synuclein rats by combining 6-[18F]fluoro-L-m-tyrosine imaging and motor performances analysis. Neurobiology of Aging, 2021, 107, 142-152.	1.5	4
23	Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiology of Aging, 2021, 107, 53-56.	1.5	4
24	Involvement of Autophagy in Levodopaâ€Induced Dyskinesia. Movement Disorders, 2021, 36, 1137-1146.	2.2	8
25	Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Frontiers in Bioengineering and Biotechnology, 2021, 9, 762209.	2.0	10
26	Nanoscale exploration of the extracellular space in the live brain by combining single carbon nanotube tracking and super-resolution imaging analysis. Methods, 2020, 174, 91-99.	1.9	41
27	Managing Parkinson's disease: moving ON with NOP. British Journal of Pharmacology, 2020, 177, 28-47.	2.7	11
28	Models of hyperkinetic disorders in primates. Journal of Neuroscience Methods, 2020, 332, 108551.	1.3	1
29	Novel self-replicating Î±-synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons. Science Advances, 2020, 6, .	4.7	49
30	CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinsonâ€™s disease. Nature Communications, 2020, 11, 4885.	5.8	39
31	Synucleinopathy alters nanoscale organization and diffusion in the brain extracellular space through hyaluronan remodeling. Nature Communications, 2020, 11, 3440.	5.8	69
32	Âµ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease. Journal of Neuroscience, 2020, 40, 6812-6819.	1.7	24
33	Overexpression of Î±-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy. Cells, 2020, 9, 2371.	1.8	15
34	Bioelectronic Interfaces: Soft, Implantable Bioelectronic Interfaces for Translational Research (Adv.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	11.1	4
35	Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates. Neurobiology of Disease, 2020, 141, 104941.	2.1	11
36	RasGRP1 is a causal factor in the development of <scp>l</scp> -DOPAâ€“induced dyskinesia in Parkinsonâ€™s disease. Science Advances, 2020, 6, eaaz7001.	4.7	33

#	Article	IF	Citations
37	Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain, 2020, 143, 1462-1475.	3.7	135
38	Identification of distinct pathological signatures induced by patient-derived Î±-synuclein structures in nonhuman primates. Science Advances, 2020, 6, eaaz9165.	4.7	34
39	Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates. Neurobiology of Disease, 2020, 141, 104951.	2.1	12
40	Targeting Î±-Synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules, 2020, 10, 391.	1.8	43
41	Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Neurobiology of Disease, 2020, 139, 104846.	2.1	8
42	Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. Neurobiology of Disease, 2020, 139, 104818.	2.1	15
43	Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy. Neurobiology of Disease, 2020, 137, 104738.	2.1	36
44	Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. Movement Disorders, 2020, 35, 1163-1172.	2.2	12
45	Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson's disease. Heliyon, 2020, 6, e05771.	1.4	4
46	Dystonia and dopamine: From phenomenology to pathophysiology. Progress in Neurobiology, 2019, 182, 101678.	2.8	53
47	Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinsonâ€™s disease. Brain, 2019, 142, 2402-2416.	3.7	16
48	Intrastriatal injection of alpha-synuclein fibrils induces Parkinson-like pathology in macaques. Brain, 2019, 142, 3321-3322.	3.7	11
49	Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders, 2019, 34, 1629-1642.	2.2	65
50	Comprehensive mapping of neurotransmitter networks by MALDIâ€“MS imaging. Nature Methods, 2019, 16, 1021-1028.	9.0	148
51	The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinsonâ€™s disease patients. Scientific Reports, 2019, 9, 8898.	1.6	31
52	<scp>l</scp>â€Dopaâ€“free learned dyskinetic behavior in a Parkinson's primate model. Movement Disorders, 2019, 34, 1237-1237.	2.2	0
53	Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 789-793.	1.4	2
54	Local transgene expression and wholeâ€body transgenesis to model brain diseases in nonhuman primate. Animal Models and Experimental Medicine, 2019, 2, 9-17.	1.3	5

#	Article	IF	Citations
55	Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Frontiers in Neurology, 2019, 10, 256.	1.1	8
56	<scp>RGS</scp> 9â€2 rescues dopamine D2 receptor levels and signaling in <i> <scp>DYT</scp> 1 </i> dystonia mouse models. EMBO Molecular Medicine, 2019, 11, .	3.3	44
57	TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nature Neuroscience, 2019, 22, 65-77.	7.1	143
58	The hidden side of Parkinsonâ€™s disease: Studying pain, anxiety and depression in animal models. Neuroscience and Biobehavioral Reviews, 2019, 96, 335-352.	2.9	42
59	NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of Disease, 2019, 121, 338-349.	2.1	24
60	Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. JCI Insight, 2019, 4, .	2.3	54
61	Synaptic Regulator Î±-Synuclein in Dopaminergic Fibers Is Essentially Required for the Maintenance of Subependymal Neural Stem Cells. Journal of Neuroscience, 2018, 38, 814-825.	1.7	16
62	Microdialysis in awake macaque monkeys for central nervous system pharmacokinetics. Animal Models and Experimental Medicine, 2018, 1, 314-321.	1.3	2
63	Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-Related Neurodegenerative Diseases. Bioconjugate Chemistry, 2018, 29, 4083-4089.	1.8	20
64	Metaâ€analysis of amantadine efficacy for improving preclinical research reliability. Movement Disorders, 2018, 33, 1555-1557.	2.2	7
65	Levodopaâ€induced dyskinesia in Parkinson disease: Current and evolving concepts. Annals of Neurology, 2018, 84, 797-811.	2.8	225
66	An m<scp>G</scp>lu4â€<scp>P</scp>ositive <scp>A</scp>llosteric <scp>M</scp>odulator <scp>A</scp>lleviates <scp>P</scp>arkinsonism in <scp>P</scp>rimates. Movement Disorders, 2018, 33, 1619-1631.	2.2	44
67	Configuration of electrical spinal cord stimulation through real-time processing of gait kinematics. Nature Protocols, 2018, 13, 2031-2061.	5.5	96
68	G2019S LRRK2 mutation facilitates Î±-synuclein neuropathology in aged mice. Neurobiology of Disease, 2018, 120, 21-33.	2.1	56
69	Inhaling xenon ameliorates <scp>l</scp>â€dopaâ€induced dyskinesia in experimental parkinsonism. Movement Disorders, 2018, 33, 1632-1642.	2.2	15
70	The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiology of Disease, 2018, 118, 64-75.	2.1	20
71	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews Drug Discovery, 2018, 17, 660-688.	21.5	370
72	Systemic Gene Delivery by Single-Dose Intracardiac Administration of scAAV2/9 and scAAV2/rh10 Variants in Newborn Rats. Human Gene Therapy Methods, 2018, 29, 189-199.	2.1	1

#	Article	IF	Citations
73	Cardinal Motor Features of Parkinsonâ€™s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia. Journal of Parkinson's Disease, 2018, 8, 323-331.	1.5	12
74	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193.	2.8	137
75	Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurology, The, 2017, 16, 238-250.	4.9	280
76	U18666A, an activator of sterol regulatory element binding protein pathway, modulates presynaptic dopaminergic phenotype of SH-SY5Y neuroblastoma cells. Synapse, 2017, 71, e21980.	0.6	9
77	In vitro Î±-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiology of Disease, 2017, 103, 101-112.	2.1	96
78	Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics, 2017, 26, 2603-2615.	1.4	37
79	Viralâ€mediated oligodendroglial alphaâ€synuclein expression models multiple system atrophy. Movement Disorders, 2017, 32, 1230-1239.	2.2	35
80	Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model. Scientific Reports, 2017, 7, 45831.	1.6	21
81	Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain, 2017, 140, 1420-1436.	3.7	80
82	Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiology of Disease, 2017, 108, 54-64.	2.1	40
83	In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinsonâ€™s disease. Gene Therapy, 2017, 24, 801-809.	2.3	8
84	Mitochondrial division inhibitor-1 is neuroprotective in the A53T-Î±-synuclein rat model of Parkinsonâ€™s disease. Scientific Reports, 2017, 7, 7495.	1.6	94
85	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, 2017, 32, 1264-1310.	2.2	608
86	A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease. European Journal of Pharmacology, 2017, 813, 10-16.	1.7	18
87	Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to Î±-synuclein targeted disease modification. Experimental Neurology, 2017, 298, 172-179.	2.0	45
88	Alterations in Functional Cortical Hierarchy in Hemiparkinsonian Rats. Journal of Neuroscience, 2017, 37, 7669-7681.	1.7	19
89	Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. Scientific Reports, 2017, 7, 2348.	1.6	6
90	Endosulfine-alpha inhibits membrane-induced Î±-synuclein aggregation and protects against Î±-synuclein neurotoxicity. Acta Neuropathologica Communications, 2017, 5, 3.	2.4	26

#	Article	IF	Citations
91	Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. Frontiers in Neuroscience, 2017, 11, 26.	1.4	110
92	Decreased Rhes mRNA levels in the brain of patients with Parkinsonâ€™s disease and MPTP-treated macaques. PLoS ONE, 2017, 12, e0181677.	1.1	12
93	Selective Inactivation of Striatal FosB/Î”FosB-Expressing Neurons Alleviates L-DOPAâ€“Induced Dyskinesia. Biological Psychiatry, 2016, 79, 354-361.	0.7	68
94	Unexpected toxicity of very low dose MPTP in mice: A clue to the etiology of Parkinson's disease?. Synapse, 2016, 70, 49-51.	0.6	12
95	Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line. Synapse, 2016, 70, 71-86.	0.6	15
96	Permeability of bloodâ€“brain barrier in macaque model of 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€induced Parkinson disease. Synapse, 2016, 70, 231-239.	0.6	11
97	Early prenatal exposure to MPTP does not affect nigrostrial neurons in macaque monkey. Synapse, 2016, 70, 52-56.	0.6	3
98	Alphaâ€synuclein propagation: New insights from animal models. Movement Disorders, 2016, 31, 161-168.	2.2	100
99	Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy. Neuropharmacology, 2016, 109, 69-77.	2.0	35
100	Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9593-9598.	3.3	89
101	An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology, 2016, 110, 48-58.	2.0	47
102	Ambroxol effects in glucocerebrosidase and Î±â€synuclein transgenic mice. Annals of Neurology, 2016, 80, 766-775.	2.8	143
103	A brainâ€“spine interface alleviating gait deficits after spinal cord injury in primates. Nature, 2016, 539, 284-288.	13.7	492
104	Antidyskinetic effect of A_{2A} and 5HT_{1A/1B} receptor ligands in two animal models of Parkinson's disease. Movement Disorders, 2016, 31, 501-511.	2.2	36
105	Targeting Î±â€synuclein: Therapeutic options. Movement Disorders, 2016, 31, 882-888.	2.2	37
106	A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Movement Disorders, 2016, 31, 1373-1380.	2.2	111
107	Inhibiting Lateral Habenula Improves L-DOPAâ€“Induced Dyskinesia. Biological Psychiatry, 2016, 79, 345-353.	0.7	18
108	Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases. Autophagy, 2016, 12, 472-483.	4.3	146

#	Article	IF	Citations
109	Spatiotemporal neuromodulation therapies engaging muscle synergies improve motor control after spinal cord injury. Nature Medicine, 2016, 22, 138-145.	15.2	274
110	Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease, 2016, 89, 55-64.	2.1	24
111	Striatal NELF-mediated RNA polymerase II stalling controls l -dopa induced dyskinesia. Neurobiology of Disease, 2016, 85, 93-98.	2.1	6
112	Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	4.9	393
113	Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinsonâ€™s disease. Neuroscience, 2015, 298, 389-396.	1.1	40
114	Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinsonâ€™s disease?. Brain, 2015, 138, 829-830.	3.7	15
115	Blood withdrawal affects iron store dynamics in primates with consequences on monoaminergic system function. Neuroscience, 2015, 290, 621-635.	1.1	28
116	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168.	2.8	379
117	Why bother using non-human primate models of cognitive disorders in translational research?. Neurobiology of Learning and Memory, 2015, 124, 123-129.	1.0	39
118	D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly. Neurobiology of Disease, 2015, 78, 77-87.	2.1	10
119	Targeting Î²-arrestin2 in the treatment of <scp>l</scp> -DOPAâ€“induced dyskinesia in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2517-26.	3.3	91
120	Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by Î±-synuclein overexpression. Acta Neuropathologica Communications, 2015, 3, 46.	2.4	88
121	Pronounced species divergence in corticospinal tract reorganization and functional recovery after lateralized spinal cord injury favors primates. Science Translational Medicine, 2015, 7, 302ra134.	5.8	148
122	Prototypic and Arkypallidal Neurons in the Dopamine-Intact External Globus Pallidus. Journal of Neuroscience, 2015, 35, 6667-6688.	1.7	200
123	M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron, 2015, 88, 762-773.	3.8	183
124	Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cerebral Cortex, 2015, 25, 2783-2792.	1.6	42
125	Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology?. Frontiers in Aging Neuroscience, 2014, 6, 258.	1.7	46
126	Lysosomes and ÃŽÂ±-synuclein form a dangerous duet leading to neuronal cell death. Frontiers in Neuroanatomy, 2014, 8, 83.	0.9	76

#	Article	IF	Citations
127	Depressive-like behavioral profiles in captive-bred single- and socially-housed rhesus and cynomolgus macaques: a species comparison. Frontiers in Behavioral Neuroscience, 2014, 8, 47.	1.0	20
128	Systemic gene delivery to the central nervous system using Adeno-associated virus. Frontiers in Molecular Neuroscience, 2014, 7, 50.	1.4	65
129	Wireless Neurosensor for Full-Spectrum Electrophysiology Recordings during Free Behavior. Neuron, 2014, 84, 1170-1182.	3.8	200
130	Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine (MPTP)â€lesioned primate model of Parkinson's disease. Movement Disorders, 2014, 29, 772-779.	2.2	37
131	Down-regulating Î±-synuclein for treating synucleopathies. Movement Disorders, 2014, 29, 1463-1465.	2.2	4
132	Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease, 2014, 62, 307-312.	2.1	25
133	Effects of l-tryptophan on l-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Neuroscience Letters, 2014, 566, 72-76.	1.0	9
134	D1 receptor agonist improves sleepâ€“wake parameters in experimental parkinsonism. Neurobiology of Disease, 2014, 63, 20-24.	2.1	37
135	Lewy body extracts from Parkinson disease brains trigger Î±â€synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology, 2014, 75, 351-362.	2.8	521
136	Direct Targeted Quantitative Molecular Imaging of Neurotransmitters in Brain Tissue Sections. Neuron, 2014, 84, 697-707.	3.8	188
137	The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Movement Disorders, 2014, 29, 1074-1079.	2.2	66
138	RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of Disease, 2014, 70, 138-148.	2.1	18
139	Multiple system atrophy: A prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiology of Disease, 2014, 67, 133-139.	2.1	28
140	Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?. Progress in Neurobiology, 2014, 118, 1-18.	2.8	185
141	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	6.3	336
142	Immediate-early gene expression in structures outside the basal ganglia is associated to l-DOPA-induced dyskinesia. Neurobiology of Disease, 2014, 62, 179-192.	2.1	63
143	L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific Reports, 2014, 4, 3730.	1.6	68
144	Viral Vectors in Primate Research: Examples from Parkinsonâ€™s Disease Research. Neuromethods, 2014, , 331-341.	0.2	2

#	ARTICLE	IF	CITATIONS
145	Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies. Movement Disorders, 2013, 28, 61-70.	2.2	156
146	Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiology of Disease, 2013, 49, 79-86.	2.1	30
147	Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neuroscience Research, 2013, 77, 242-246.	1.0	44
148	Levodopaâ€“induced dyskinesias in the absence of nigrostriatal degeneration. Movement Disorders, 2013, 28, 1023-1024.	2.2	5
149	Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (â€œn-of-1â€) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Parkinsonism and Related Disorders, 2013, 19, 416-421.	1.1	27
150	Levodopa gains psychostimulantâ€like properties after nigral dopaminergic loss. Annals of Neurology, 2013, 74, 140-144.	2.8	43
151	Lysosomal impairment in Parkinson's disease. Movement Disorders, 2013, 28, 725-732.	2.2	270
152	Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model. Movement Disorders, 2013, 28, 663-667.	2.2	32
153	D1 Dopamine Receptor-Mediated LTP at GABA Synapses Encodes Motivation to Self-Administer Cocaine in Rats. Journal of Neuroscience, 2013, 33, 11960-11971.	1.7	43
154	Dopamine-Dependent Long-Term Depression at Subthalamo-Nigral Synapses Is Lost in Experimental Parkinsonism. Journal of Neuroscience, 2013, 33, 14331-14341.	1.7	29
155	Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18005-18010.	3.3	92
156	Study of the antidyskinetic effect of eltoprazine in animal models of levodopaâ€induced dyskinesia. Movement Disorders, 2013, 28, 1088-1096.	2.2	128
157	Behavioural Profiles in Captive-Bred Cynomolgus Macaques: Towards Monkey Models of Mental Disorders?. PLoS ONE, 2013, 8, e62141.	1.1	37
158	Birth Origin Differentially Affects Depressive-Like Behaviours: Are Captive-Born Cynomolgus Monkeys More Vulnerable to Depression than Their Wild-Born Counterparts?. PLoS ONE, 2013, 8, e67711.	1.1	19
159	l-DOPA Impairs Proteasome Activity in Parkinsonism through D₁Dopamine Receptor. Journal of Neuroscience, 2012, 32, 681-691.	1.7	37
160	Modeling Parkinson's Disease in Primates: The MPTP Model. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009308-a009308.	2.9	131
161	Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias. Journal of Neuroscience, 2012, 32, 16106-16119.	1.7	39
162	Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Scientific Reports, 2012, 2, 253.	1.6	29

#	Article	IF	Citations
163	Age-dependent Î±-synuclein aggregation in the Microcebus murinus lemur primate. Scientific Reports, 2012, 2, 910.	1.6	21
164	Altered pallidoâ€pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease. Journal of Physiology, 2012, 590, 5861-5875.	1.3	76
165	Lysosomal dysfunction in Parkinson disease. Autophagy, 2012, 8, 1389-1391.	4.3	69
166	Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9611-9616.	3.3	309
167	Coordinated reset has sustained aftereffects in Parkinsonian monkeys. Annals of Neurology, 2012, 72, 816-820.	2.8	249
168	A critique of available scales and presentation of the nonâ€human primate dyskinesia rating scale. Movement Disorders, 2012, 27, 1373-1378.	2.2	62
169	PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. Journal of Clinical Investigation, 2012, 122, 3977-3989.	3.9	110
170	Molecular Mechanisms of l-DOPA-Induced Dyskinesia. International Review of Neurobiology, 2011, 98, 95-122.	0.9	47
171	Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia. Neuroscience, 2011, 198, 245-251.	1.1	98
172	Double-Dissociation of the Catecholaminergic Modulation of Synaptic Transmission in the Oval Bed Nucleus of the Stria Terminalis. Journal of Neurophysiology, 2011, 105, 145-153.	0.9	48
173	Priorities in Parkinson's disease research. Nature Reviews Drug Discovery, 2011, 10, 377-393.	21.5	364
174	New animal models of Parkinson's disease. Movement Disorders, 2011, 26, 1198-1205.	2.2	36
175	A tale on animal models of Parkinson's disease. Movement Disorders, 2011, 26, 993-1002.	2.2	130
176	Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain, 2011, 134, 2321-2338.	3.7	29
177	A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiology of Disease, 2010, 39, 352-361.	2.1	142
178	Maladaptive plasticity of serotonin axon terminals in levodopaâ€induced dyskinesia. Annals of Neurology, 2010, 68, 619-628.	2.8	221
179	Synaptic recruitment of AMPA glutamate receptor subunits in levodopaâ€induced dyskinesia in the MPTPâ€lesioned nonhuman primate. Synapse, 2010, 64, 177-180.	0.6	65
180	Distinct Changes in cAMP and Extracellular Signal-Regulated Protein Kinase Signalling in L-DOPA-Induced Dyskinesia. PLoS ONE, 2010, 5, e12322.	1.1	111

#	Article	IF	Citations
181	Neuroanatomical Study of the A11 Diencephalospinal Pathway in the Non-Human Primate. PLoS ONE, 2010, 5, e13306.	1.1	82
182	Lentiviral Overexpression of GRK6 Alleviates <scp>l</scp> -Dopaâ€"Induced Dyskinesia in Experimental Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 28ra28.	5.8	127
183	Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with <scp>l</scp> -dopaâ€"induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21824-21829.	3.3	141
184	Dopamine Transporter Binding Is Unaffected by L-DOPA Administration in Normal and MPTP-Treated Monkeys. PLoS ONE, 2010, 5, e14053.	1.1	48
185	Pharmacological Analysis Demonstrates Dramatic Alteration of D₁Dopamine Receptor Neuronal Distribution in the Rat Analog of l-DOPA-Induced Dyskinesia. Journal of Neuroscience, 2009, 29, 4829-4835.	1.7	128
186	Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurology, The, 2009, 8, 1140-1149.	4.9	337
187	Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterology and Motility, 2009, 21, 215-222.	1.6	75
188	Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model. Experimental Neurology, 2009, 219, 574-582.	2.0	124
189	Priming for l-dopa-induced dyskinesia in Parkinsonâ€™s disease: A feature inherent to the treatment or the disease?. Progress in Neurobiology, 2009, 87, 1-9.	2.8	116
190	Antagonizing L-type Ca2+ Channel Reduces Development of Abnormal Involuntary Movement in the Rat Model of L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia. Biological Psychiatry, 2009, 65, 518-526.	0.7	78
191	Striatal Overexpression of Î"JunD Resets L-DOPA-Induced Dyskinesia in a Primate Model of Parkinson Disease. Biological Psychiatry, 2009, 66, 554-561.	0.7	89
192	Dopamine receptors and l-dopa-induced dyskinesia. Parkinsonism and Related Disorders, 2009, 15, S8-S12.	1.1	48
193	Striatal histone modifications in models of levodopaâ€induced dyskinesia. Journal of Neurochemistry, 2008, 106, 486-494.	2.1	92
194	Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience, 2008, 153, 1213-1224.	1.1	65
195	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.	3.7	223
196	The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's Disease. Journal of Neuroscience, 2008, 28, 4311-4316.	1.7	83
197	Striatal Proteomic Analysis Suggests that First L-Dopa Dose Equates to Chronic Exposure. PLoS ONE, 2008, 3, e1589.	1.1	45
198	Noradrenergic Modulation of Subthalamic Nucleus Activity: Behavioral and Electrophysiological Evidence in Intact and 6-Hydroxydopamine-Lesioned Rats. Journal of Neuroscience, 2007, 27, 9595-9606.	1.7	60

#	Article	IF	Citations
199	RGS9â€“2 Negatively Modulates l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Experimental Parkinson's Disease. Journal of Neuroscience, 2007, 27, 14338-14348.	1.7	116
200	Enhanced Preproenkephalin-Bâ€“Derived Opioid Transmission in Striatum and Subthalamic Nucleus Converges Upon Globus Pallidus Internalis in L-3,4-dihydroxyphenylalanineâ€“Induced Dyskinesia. Biological Psychiatry, 2007, 61, 836-844.	0.7	82
201	Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. European Journal of Neuroscience, 2007, 25, 1492-1500.	1.2	26
202	Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiology of Disease, 2007, 26, 452-463.	2.1	130
203	Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. European Journal of Neuroscience, 2006, 24, 1201-1208.	1.2	51
204	Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracelullar striatal dopamine. Neurobiology of Disease, 2006, 22, 586-598.	2.1	134
205	5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiology of Disease, 2006, 23, 77-86.	2.1	64
206	Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: A proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. BMC Bioinformatics, 2006, 7, 475.	1.2	37
207	Phenotype of Striatofugal Medium Spiny Neurons in Parkinsonian and Dyskinetic Nonhuman Primates: A Call for a Reappraisal of the Functional Organization of the Basal Ganglia. Journal of Neuroscience, 2006, 26, 8653-8661.	1.7	76
208	Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. European Journal of Neuroscience, 2005, 22, 283-287.	1.2	74
209	Increased D1dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology, 2005, 57, 17-26.	2.8	356
210	Involvement of Sensorimotor, Limbic, and Associative Basal Ganglia Domains in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia. Journal of Neuroscience, 2005, 25, 2102-2107.	1.7	83
211	l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiology of Disease, 2005, 18, 323-335.	2.1	94
212	Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism and Related Disorders, 2005, 11, S25-S29.	1.1	113
213	Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology, 2005, 48, 503-516.	2.0	175
214	Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 770-777.	1.3	46
215	Levetiracetam Potentiates the Antidyskinetic Action of Amantadine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 386-394.	1.3	74
216	Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. European Journal of Neuroscience, 2004, 19, 3266-3276.	1.2	156

#	Article	IF	Citations
217	Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology, 2004, 485, 159-164.	1.7	62
218	Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Experimental Neurology, 2004, 189, 1-4.	2.0	83
219	Levetiracetam Interferes With the l-Dopa Priming Process in MPTP-Lesioned Drug-Naive Marmosets. Clinical Neuropharmacology, 2004, 27, 171-177.	0.2	21
220	Time-Course of Nigrostriatal Degeneration in a Progressive MPTP-Lesioned Macaque Model of Parkinson's Disease. Molecular Neurobiology, 2003, 28, 209-218.	1.9	76
221	Neuroprotection for Parkinson's disease: a call for clinically riven experimental design. Lancet Neurology, The, 2003, 2, 393.	4.9	17
222	Novel antiepileptic drug levetiracetam decreases dyskinesia elicited byL-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders, 2003, 18, 1301-1305.	2.2	51
223	Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. Journal of Neurochemistry, 2003, 84, 1246-1255.	2.1	43
224	Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine, 2003, 9, 762-767.	15.2	370
225	Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT. NeuroImage, 2003, 19, 810-816.	2.1	37
226	Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends in Neurosciences, 2003, 26, 215-221.	4.2	309
227	Enriched Environment Confers Resistance to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine and Cocaine: Involvement of Dopamine Transporter and Trophic Factors. Journal of Neuroscience, 2003, 23, 10999-11007.	1.7	206
228	Upregulation of Striatal Preproenkephalin Gene Expression Occurs before the Appearance of Parkinsonian Signs in 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine Monkeys. Neurobiology of Disease, 2001, 8, 343-350.	2.1	59
229	Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience, 2001, 103, 117-123.	1.1	25
230	Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nature Reviews Neuroscience, 2001, 2, 577-588.	4.9	472
231	Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain, 2001, 124, 546-557.	3.7	180
232	Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinsonâ€™s disease. FASEB Journal, 2001, 15, 1092-1094.	0.2	56
233	Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease. Journal of Neuroscience, 2001, 21, 6853-6861.	1.7	437
234	Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB Journal, 2001, 15, 1092-1094.	0.2	3

#	Article	IF	Citations
235	Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. European Journal of Neuroscience, 2000, 12, 2892-2900.	1.2	70
236	Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. Journal of Neuroscience Methods, 2000, 96, 71-76.	1.3	142
237	Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. European Journal of Neuroscience, 1999, 11, 2167-2170.	1.2	136
238	Absence of MPTP-Induced Neuronal Death in Mice Lacking the Dopamine Transporter. Experimental Neurology, 1999, 155, 268-273.	2.0	190
239	Effects of l-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Research, 1998, 787, 157-160.	1.1	177
240	Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach. Progress in Neurobiology, 1998, 55, 93-116.	2.8	193
241	Experimental Models of Parkinson's Disease: From the Static to the Dynamic. Reviews in the Neurosciences, 1998, 9, 71-90.	1.4	70
242	Subthalamic stimulation elicits hemiballismus in normal monkey. NeuroReport, 1997, 8, 1625-1629.	0.6	39
243	Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neuroscience Letters, 1997, 234, 47-50.	1.0	70
244	Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental Parkinsonism. Neuroscience, 1997, 81, 399-404.	1.1	60
245	A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Research, 1997, 766, 107-112.	1.1	157
246	High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey. Neuroscience Letters, 1996, 215, 17-20.	1.0	244